Enrollment finished ahead of schedule in a Phase 2 trial testing Calluna Pharma’s experimental CAL101 therapy in adults with ...

Columnist Sam Kirton writes about the passing of a friend with whom he shared a diagnosis of IPF, and reflects on his own patient journey.

Fast shallow breathing (tachypnea) is one of several breathing difficulties experienced by pulmonary fibrosis (PF) patients. Breathing problems are common in PF because the disease causes progressive ...

Abnormalities in DNA methylation, a genetic modification, may affect disease risk in idiopathic pulmonary fibrosis, according ...

Since leaving the workforce due to IPF, columnist Sam Kirton has been volunteering to be of service to his PF and local communities.

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

Ofev (nintedanib), an oral medication by Boehringer Ingelheim, is now approved to treat people with progressive fibrosing interstitial lung diseases (ILDs) in the U.S. and Canada. Ofev is the first ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...